utatrectinib   Click here for help

GtoPdb Ligand ID: 10360

Synonyms: AZ12607092 | AZD-7451 | AZD7451 | Example 6 [US8486966B2]
Compound class: Synthetic organic
Comment: AZD7451 is a pan tropomyosin receptor kinase (TRK; also know as neurotrophic receptor tyrosine kinases or NTRKs) inhibitor [1]. It reached Phase 1 clinical development for anticancer potential, but the programme was discontinued. It was designed for the treatment of tumours that express oncogenic NTRK fusions [2-3]. The chemical structure of AZD7451 is identical to that which was submitted to the WHO for the INN utatrectinib (proposed INN list 126, Jan 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 105.91
Molecular weight 382.17
XLogP 3.62
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(c1ncc(cn1)F)Nc1ccc2c(n1)n(cn2)c1cc([nH]n1)OC(C)C
Isomeric SMILES C[C@@H](c1ncc(cn1)F)Nc1ccc2c(n1)n(cn2)c1cc([nH]n1)OC(C)C
InChI InChI=1S/C18H19FN8O/c1-10(2)28-16-6-15(25-26-16)27-9-22-13-4-5-14(24-18(13)27)23-11(3)17-20-7-12(19)8-21-17/h4-11H,1-3H3,(H,23,24)(H,25,26)/t11-/m0/s1
InChI Key AYOOGWWGECJQPI-NSHDSACASA-N
No information available.
Summary of Clinical Use Click here for help
AZD7451 completed Phase 1 evaluation in patients with recurrent gliomas (NCT01468324), but development has not been progressed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01468324 AZD7451 for Recurrent Gliomas Phase 1 Interventional National Institutes of Health Clinical Center (CC)